Visit LathamDrive – A new site with resources to help emerging companies grow.

Recognized as a Rising Star in Northern California.Super Lawyers 2013-2017

Benjamin A. Potter

Silicon Valley
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA

Benjamin Potter is a partner in the Silicon Valley office and serves as Global Vice Chair of the Emerging Companies Practice and Co-Chair of the Technology Industry Group. He represents emerging companies, venture capital and private equity firms, and investment banks involved in the technology, life sciences, and cleantech industries. His practice focuses on general corporate counseling, venture capital financings, mergers and acquisitions, and public offerings.

Mr. Potter’s general company representation includes assistance with formation issues, employment matters, equity incentives, securities law compliance, negotiation of license agreements, and advising boards of directors regarding corporate governance matters.

Prior to joining Latham, Mr. Potter worked at IBM Global Services and two education startup companies in New York City.

Mr. Potter received his JD, cum laude, from the University of Michigan Law School in 2006 where he was contributing editor of the Michigan Law Review, and his MBA from the University of Michigan Business School, also in 2006. He received his BA in History, with Distinction, from Yale University in 1998.


Mr. Potter’s representative technology transactions include:

  • Impossible Foods – US$108 million Series D Financing
  • OpenGov – US$25.7 million Series B Financing
  • Duolingo – US$3 million Series A Financing, US$15 million Series B Financing, US$20 million Series C Financing, and US$45 million Series D Financing
  • Light – US$30 million Series C Financing
  • Area 1 Security – US$2.5 million Seed Financing and US$15 million Series B Financing
  • 8VC – venture financings for Sudo, Bloomz, Common Living, HONOR, and others
  • Eclipse Ventures – venture financings for Inbox App, Flex Logic, Swift Navigation 6 River Systems, and others
  • Andreessen Horowitz - venture financings for Soylent, Nootrobox, TwoXAR, Rappi, Tesla Health, Accolade, and others
  • Formation 8 – venture financings for, Radius Intelligence, NextVR, Farmigo, Grabit., Illumio, Chobolabs, Memebox, Inbox App, Oscar Health Insurance, and others
  • Meritech Capital – venture financings for Looker Data Sciences, Guidespark, Ionic Security, ServiceMax, and others

Mr. Potter’s representative life sciences transactions include:

  • Tizona Therapeutics – US$43 million Series B Financing
  • Avalanche Biotechnologies – US$55 million Series B Financing, US$640 million strategic collaboration with Regeneron Pharmaceutical, US$117.3 million initial public offering, and US$130.5 million follow-on offering
  • Coherus Biosciences – US$85 million initial public offering, US$120 million follow-on offering, and US$63 million follow-on offering
  • Afferent Pharmaceuticals – US$55 million Series C Financing and US$1.25 billion sale of Afferent Pharmaceuticals to Merck & Co.  
  • Alios BioPharma – US$1.75 billion sale of Alios BioPharma to Johnson & Johnson
  • Envoy Therapeutics – US$140 million sale of Envoy Therapetuics to Takeda Pharmaceutical Company Limited
  • Pearl Therapeutics – US$1.15 billion sale to AstraZeneca
  • Plexxikon – US$805 million up-front sale to Daiichi Sankyo Company, near-term milestone payments could total an additional US$130 million
  • Jefferies - US$46.2 million initial public offering of Aquinox
Representative Clients

Andreessen Horowitz
Area 1 Security
Calysta Energy
Coherus BioSciences
Crossover Health
Gurnet Point Capital
Imago BioSciences
Impossible Foods
Nozomi Networks
Pionyr Immunotherapeutics
Tizona Therapeutics

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.